Document Detail


Emerging clinical role of ranolazine in the management of angina.
MedLine Citation:
PMID:  21063462     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Chronic stable angina is an exceedingly prevalent condition with tremendous clinical, social, and financial implications. Traditional medical therapy for angina consists of beta-blockers, calcium channel blockers, and nitrates. These agents decrease myocardial oxygen demand and ischemia by reducing heart rate, lowering blood pressure, and/or optimizing ventricular loading characteristics. Unique in its mechanism of action, ranolazine is the first new antianginal agent approved for use in the US for chronic angina in over 25 years. By inhibiting the late inward sodium current (I(Na)), ranolazine prevents pathologic intracellular calcium accumulation that leads to ischemia, myocardial dysfunction, and electrical instability. Ranolazine has been proven in multiple clinical trials to reduce the symptoms of angina safely and effectively and to improve exercise tolerance in patients with symptomatic coronary heart disease. These benefits occur without reduction in heart rate and blood pressure or increased mortality. Although ranolazine prolongs the QT(c), experimental data indicate that ranolazine may actually be antiarrhythmic. In a large acute coronary syndrome clinical trial, ranolazine reduced the incidence of supraventricular tachycardia, ventricular tachycardia, new-onset atrial fibrillation, and bradycardic events. Additional benefits of ranolazine under investigation include reductions in glycosylated hemoglobin levels and improved left ventricular function. Ranolazine is a proven antianginal medication in patients with symptomatic coronary heart disease, and should be considered as an initial antianginal agent for those with hypotension or bradycardia.
Authors:
David S Vadnais; Nanette K Wenger
Publication Detail:
Type:  Journal Article     Date:  2010-10-21
Journal Detail:
Title:  Therapeutics and clinical risk management     Volume:  6     ISSN:  1178-203X     ISO Abbreviation:  Ther Clin Risk Manag     Publication Date:  2010  
Date Detail:
Created Date:  2010-11-10     Completed Date:  2011-07-14     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  101253281     Medline TA:  Ther Clin Risk Manag     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  517-30     Citation Subset:  -    
Affiliation:
Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment of Cushing disease: overview and recent findings.
Next Document:  Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: focus o...